BIOGEN INC. Available-for-sale Securities, Gross Unrealized Loss
BIOGEN INC. (BIIB) reported Available-for-sale Securities, Gross Unrealized Loss of $300.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2014-02-06
- BIOGEN INC. available-for-sale securities, gross unrealized loss for the quarter ending 2013-12-31 was $600.00K.
- BIOGEN INC. available-for-sale securities, gross unrealized loss for the quarter ending 2013-09-30 was -$100.00K.
- BIOGEN INC. available-for-sale securities, gross unrealized loss for the quarter ending 2011-03-31 was -$1.40M.
- BIOGEN INC. available-for-sale securities, gross unrealized loss for the quarter ending 2010-12-31 was -$900.00K.
- BIOGEN INC. available-for-sale securities, gross unrealized loss for fiscal 2013 was $300.00K, a 84.21% decline from fiscal 2012.
- BIOGEN INC. available-for-sale securities, gross unrealized loss for fiscal 2012 was $1.90M.
- BIOGEN INC. available-for-sale securities, gross unrealized loss for fiscal 2009 was -$1.30M.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month | Available-for-sale Securities, Gross Unrealized Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2013-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $500.00K derived: sum of 2 quarters · filed 2014-02-06 | $300.00K 10-K · filed 2014-02-06 | ||
| 2013-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | -$300.00K 10-Q · filed 2013-10-28 | |||
| 2013-06-30 | -$200.00K 10-Q · filed 2013-07-25 | ||||
| 2012-12-31 | $1.90M 10-K · filed 2014-02-06 | -$1.90M 10-Q · filed 2013-07-25 | |||
| 2011-03-31 | -$1.40M 10-Q · filed 2011-04-21 | -$2.30M derived: sum of 2 quarters · filed 2011-04-21 | -$2.40M derived: sum of 3 quarters · filed 2011-04-21 | ||
| 2010-12-31 | -$900.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2011-04-21 | -$1.00M derived: sum of 2 quarters · filed 2011-04-21 | -$1.30M 10-Q · filed 2011-04-21 | ||
| 2010-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | -$400.00K 10-Q · filed 2010-10-26 | |||
| 2010-06-30 | -$300.00K 10-Q · filed 2010-07-20 | ||||
| 2009-12-31 | -$1.30M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |